Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development
SEATTLE, WA, August 1, 2004 (Globe Newswire) Outpace Bio, a cell therapy company using unrivaled AI-powered protein design to program immune cells for improved function inside patients battling solid tumors, today announced that it has raised $144 million in an oversubscribed Series B financing. FLG partner Greg Curhan, assisted. Read…Read More
Read MoreCap Hill Brands Merges with Juvo+ to form Infinite Commerce
March 8, 2024 (Geekwire.com) – Seattle-based Cap Hill Brands, which raised more than $250 million to acquire and grow e-commerce shops, has merged with Juvo+, a company that focuses on developing and selling its own products online. Terms of the all-stock deal were not disclosed. The combined company is now…Read More
Read MoreNuvation Bio to Acquire AnHeart Therapeutics in All Stock Transaction
New York, NY, March 25, 2024 – Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, and AnHeart Therapeutics Ltd. (AnHeart), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today…Read More
Read MoreNektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
SAN FRANCISCO, March 4, 2024 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced that it has entered into a securities purchase agreement with TCGX, an institutional accredited investor, to sell securities in a private placement financing (the “PIPE”) for gross…Read More
Read MoreAdverum Biotechnologies Announces $127.5 Million Private Placement Financing
REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that it has agreed to sell approximately 106.25 million shares of its common stock…Read More
Read More